LSV Asset Management
ALXN

LSV Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

LSV Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,710,802
Closed -$314M – 934
2021
Q2 		$314M Sell
1,710,802
-888,580
-34% -$153M 0.53% 48
2021
Q1 		$397M Sell
2,599,382
-760,704
-23% -$118M 0.68% 32
2020
Q4 		$525M Sell
3,360,086
-182,812
-5% -$23.5M 0.95% 16
2020
Q3 		$405M Buy
3,542,898
+43,464
+1% +$4.69M 0.83% 24
2020
Q2 		$393M Buy
3,499,434
+2,650,007
+312% +$281M 0.81% 26
2020
Q1 		$76.3M Buy
849,427
+178,677
+27% +$17.5M 0.18% 143
2019
Q4 		$72.5M Buy
670,750
+661,950
+7,522% +$70.8M 0.11% 211
2019
Q3 		$861K Buy
+8,800
New +$992K ﹤0.01% 759

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $280B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return